Radiology, Abdominal Imaging
-
-
Administers Grant
-
3V2640-CLIN-005 A Phase 2, Multi-Center, Single-Blind, Randomized Placebo Controlled Study of TVB-2640 in Subjects with Non-Alcoholic Steatohepatitis
-
A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients with known or Suspected Focal Liver Lesions and Severe Renal Impairment
-
A PHASE 1 STUDY TO EVALUATE THE SAFETY,
TOLERABILITY, PHARMACOKINETICS AND
PHARMACODYNAMICS OF MULTIPLE DOSES OF
HM15211 IN OBESE SUBJECTS WITH NAFLD AND IN
SUBJECTS WITH NASH
-
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF21) IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 LIVER FIBROSIS.
-
A Phase 1b, Open-Label, Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Adult Patients with Presumed Nonalcoholic Steatohepatitis (NASH)
-
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients with Presumed Nonalcoholic Steatohepatitis
-
A Phase 2b Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects with Liver Biopsy Proven Non-Alcoholic Steatohepatitis (NASH)"
-
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of BIO89-100
-
A randomized, open label, phase 1b study to evaluate safety, PK and PD signals of DUR-928 in patients with Non-Alcoholic Steatohepatitis (NASH)
-
Abbreviated MRI for HCC screening in cirrhotic patients
-
BIO89-100-122 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BIO89-100 in Subjects with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
-
Body MR Imaging 2014
-
Body MR Imaging 2015
-
Body MR Imaging 2017
-
CB8025-21845 entitled "A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients with Primary Sclerosing Cholangitis
-
CT Research Fellowship in Dual Energy and Deep Learning Image Reconstruction
-
CT-868 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Center Study to Evaluate the Efficacy, Safety, and Tolerability of CT-868 Administered for 26 Weeks to Obese Patients wi
-
Characterization of Early Anti-Angiogensis Treatment Effects in Colorectal Carcinoma Using High-Resolution Dynamic Contrast-Enhanced Ultrasound and Magnetic Resonance Imaging
-
Collaboration for assessment of 129Xe MRI hardware
-
Comparison of image quality features with new image processing methods
-
Decreased Variability for Robust Imaging-based Quantification of Tumor Heterogeneity
-
Determine the effect of CT-001 on liver PDFF and abdominal adiposity in a NAFLD population
-
Determine the effect of GH509 on liver PDFF in a NASH population
-
Development of an Optimized Single Breath Hold, Body MRI Protocol using 4D Dynamic Imaging for Fast, Motion-Free Dyanmic T1-Weighted Imaging
-
Dual-Shot NCOM Power Contract Injector Study
-
Duke Bashir Body Elastography MR
-
Fully Automated High-Throughput Quantitative MRI of the Liver
-
Image Rich Radiology Reports: A Value-Based Model to Improve Clinical Workflow
-
Imaging Core Lab for Madrigal Protocol MGL-3196-05 (A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis)
-
LLF580X2102: Analysis of fatty acids as marker of metabolite abnormalities
-
Liver surface nodularity score as a new noninvasive biomarker for chronic viral hepatitis
-
LowEr Administered Dose with highEr Relaxivity: Gadovist vs Dotarem (LEADER 75)
-
MAD05 MGL-3196 on liver PDFF and stiffness (measured by MR Elastography) in a NAFLD population
-
Madrigal MGL-3196-11: A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or
-
Madrigal MGL-3196-14 "A 52-Week Phase 3 Study of Resmetirom (MGL-3196)
-
Optimization of a Frequency-Based Fusion Technique for Improving the Image Quality on Low Energy Virtual Monochromatic Images from Dual Energy CT
-
Optimizing Preoperative Assessment and Postoperative Management of Bariatric Surgery Patients with Fully Automated, High Throughput and Normalized CT-Based Body Composition Analysis
-
Participation in Observership Program at Duke University
-
Philips' IntelliSpace Precision Medicine (ISPM) platform and its prostate cancer application(s)
-
Photon Counting Computed Tomography for Detection of Small Liver Metastases: Comparison to Conventional and Dual-Energy Systems
-
Prediction of clinically significant prostate cancer and prostate¿cancer related outcomes from only T2 weighted imaging using machine learning
-
Prospective clinical evaluation of photon-counting CT for body oncology applications through investigational patient studies
-
Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) of Bone Marrow In Acute Myeloid Leukemia
-
Randomized, Blinded, Placebo-Controlled Crossover Study Assessing Association Between Gadolinum-Based Contrast Agent Administration and Transient Severe Dyspnea\Arterial Phase Motion
-
Realizing Consistent Combined Hepatic MR Arteriography and Late Arterial Phase Imaging with Eovist
-
The imaging objective of this study is to determine the effect of MET642 on liver PDFF in patients with nonalcoholic steatohepatitis (NASH).
-
The imaging objectives of this study are to determine the effect of MGL-3196 on liver PDFF and stiffness (measured by MR Elastography) in a NAFLD population for the following:
-
Toward Precise and Accurate Assessment of Dose Reduction Using Iterative Reconstruction Methods for Abdominal Imaging Applications